Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 639 of 5804
-
Could a Muscle-Building drug boost weight loss? new trial tests bimagrumab with semaglutide
Disease control CompletedA phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo aims to fight recurrent brain tumors
Disease control Recruiting nowThis is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a robust anti-tumor immune res…
Phase: PHASE2 • Sponsor: Stephen Bagley, MD, MSCE • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug shows promise for slowing lung scarring in major trial
Disease control CompletedThis study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study. If they already take nintedanib, they can continue treatment throughout the study. Th…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Targeted therapy boost for aggressive uterine cancer under study
Disease control Recruiting nowThis phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive e…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug TAK-341 tested in rare brain disease trial
Disease control CompletedThe main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS). The study will enroll approximately 138 patients. Participants will receive a total of 13 intrave…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for young cancer patients: glofitamab trial targets tough lymphoma
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refr…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for ALS: experimental drug aims to slow muscle decline
Disease control Recruiting nowThe purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Beating-Heart surgery offers hope for stiff heart muscle patients
Disease control OngoingThe primary purpose of this study is to evaluate the feasibility, the safety and the efficacy of the transapical beating-heart myectomy for the treatment of apical hypertrophic cardiomyopathy. This is a prospective, single-arm, single-center study.
Phase: NA • Sponsor: Xiang Wei • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New scan could spot pancreatic cancer more clearly
Diagnosis Recruiting nowThis phase II trial tests whether 68Ga-FAPI-46 positron emission tomography (PET)/computed tomography (CT) scan works to image cancer-associated fibroblasts (CAFs) in patients with pancreatic ductal adenocarcinoma (PDA) that has not spread to other parts of the body (localized). …
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
New program aims to stop mental health crisis in kids from hard-hit communities
Prevention Recruiting nowRacial and ethnic minority children who live in socioeconomically disadvantaged communities are disproportionately impacted by pandemic and climate-induced disasters. Although effective interventions have been designed to treat mental health related symptoms in post-disaster sett…
Phase: NA • Sponsor: University of Illinois at Urbana-Champaign • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
New surgical tools aim to make womb surgery for spina bifida safer
Disease control Recruiting nowThe purpose of the study is to evaluate the safety and efficacy of devices used in patients undergoing fetoscopic neural tube defect repair.
Phase: NA • Sponsor: Michael A Belfort • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New heart pump driver could be lifeline for kids awaiting transplants
Disease control ENROLLING_BY_INVITATIONThe purpose of this study is to evaluate the device performance and monitor the safety and effectiveness of the Berlin Heart EXCOR Active Driving System while being used with the approved EXCOR Pediatric Ventricular Assist Device. EXCOR Active Driving System is intended for use …
Phase: NA • Sponsor: Berlin Heart, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph node…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Immune booster: could donor NK cells help kids beat sarcoma?
Disease control Recruiting nowThe purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people with childhood sarcomas that have relapsed …
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo extends life for aggressive lung cancer patients
Disease control OngoingSmall cell lung cancer (SCLC), characterized by rapid proliferation, high growth fraction and early development of metastases, is the most aggressive form of lung cancer. In 2021, an estimated 2.3 million people around the world are diagnosed with lung cancer. In France, in 2018,…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Triple-Drug cocktail aims to shrink head and neck tumors
Disease control OngoingThe purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/m…
Phase: PHASE2 • Sponsor: Incyte Biosciences International Sàrl • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for leukemia patients: asciminib trial underway
Disease control OngoingThis will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Lung cancer drug gets a shot in the arm: new subcutaneous formula tested
Disease control Recruiting nowThe purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort …
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
5-Minute heart scan could slash ER overcrowding and save billions
Diagnosis CompletedChest pain is one of the most common reasons people visit the Emergency Department (ED). While most cases are not serious, a small number may lead to life-threatening heart problems, known as Major Adverse Cardiac Events (MACE). Emergency staff need to quickly identify these high…
Phase: PHASE4 • Sponsor: Singapore General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
New chemo combo aims to boost leukemia survival after transplant
Disease control OngoingThis is a prospective, multicenter, phase II, open-label, non-randomized clinical trial designed to evaluate the safety and efficacy of the Fludarabine plus Treosulfan 14 g/m² (FT14) conditioning regimen for allogeneic stem cell transplantation (allo-SCT) in patients with Acute M…
Phase: PHASE2 • Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC